-+ 0.00%
-+ 0.00%
-+ 0.00%

DiaMedica Q2 FY26 net loss widens to $10.14 million; R&D expenses climb to $8.15 million

PUBT·08/10/2026 20:55:25
Listen to the news
DiaMedica Q2 FY26 net loss widens to $10.14 million; R&D expenses climb to $8.15 million
  • DiaMedica posted a Q2 net loss of USD 10.1 million, widening from USD 7.7 million a year earlier; loss per share was USD 0.19.
  • R&D expense rose to USD 8.2 million from USD 5.8 million; G&A edged up to USD 2.3 million from USD 2.2 million.
  • Cash, cash equivalents and investments fell to USD 43.5 million at June 30 from USD 59.9 million at year-end; runway forecast through 2027.
  • Phase 2 early-onset fetal growth restriction trial completed enrollment for its first cohort of 6 participants; topline results expected in September.
  • ReMEDy2 acute ischemic stroke trial enrollment topped 85% of the 200 participants needed for interim analysis, targeted for early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608101630BIZWIRE_USPR_____20260810_BW989621) on August 10, 2026, and is solely responsible for the information contained therein.